Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides

Tissue Antigens

Volumn 52, Issue 6, 1998, Pages 520-529

  Benitez, R ^a   Godelaine, D ^b   Lopez Nevot, M A ^a   Brasseur, F ^b   Jimenez P ^a   Marchand, M ^b   Oliva, M R ^a   Van Baren, N ^b   Cabrera, T ^a   Andry, G ^c   Landry, C ^b   Ruiz Cabello, F ^a   Boon, T ^b   Garrido, Federico ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

Author keywords

HLA; MAGE; Melanoma; 2 microglobulin

Indexed keywords

BETA 2 MICROGLOBULIN; HLA ANTIGEN CLASS 1; CANCER VACCINE; MAGEA1 PROTEIN, HUMAN; MAGEA3 PROTEIN, HUMAN; PEPTIDE; RECOMBINANT VACCINE; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN PRESENTATION; ARTICLE; CASE REPORT; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; MELANOMA CELL; PRIORITY JOURNAL; START CODON; STOP CODON; CELL CULTURE; GENETICS; IMMUNOLOGY; MELANOMA; MOLECULAR GENETICS; MUTATION; NUCLEOTIDE SEQUENCE;

ANTIGENS, NEOPLASM; BASE SEQUENCE; BETA 2-MICROGLOBULIN; CANCER VACCINES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM PROTEINS; PEPTIDES; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

EID: 0032217242     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-0039.1998.tb03082.x     Document Type: Article

References (24)

1. Van den Eynde B, van der Bruggen P. T-cell defined tumor antigens. Curr Opin Immunol 1997; 9: 684-93.
2. Van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
3. De Plaen E, Arden K, Traversari C et al. Structure, chromosomal localization and expression of twelve genes of the MAGE family. Immunogenetics 1994; 40: 360-9.
4. Gaugler B, Van den Eynde B, van der Bruggen P et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921-34.
5. Marchand M, Weynants P, Rankin E et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 883-5.
6. Jäger E, Ringhoffer M, Altmannsberger M et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997; 71: 142-7.
7. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-7.
8. Marchand M, van Baren N, Weynants P et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (In press).
9. Lopez-Nevot MA, Garcia E, Romero C, Oliva MR, Serrano S, Garrido F. Phenotypic and genetic analysis of HLA class I and HLA DR antigen expression on human melanomas. Exp Clin Immunogenet 1987; 5: 203-12.
10. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells. Molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-94.
11. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumors. Immunol Today 1997; 18: 89-95.
12. Brasseur F. Melanoma: Brussels melanoma cell lines. In: Masters JRW, Palsson B, ed. Human cell culture. Vol I. Lancaster: Kluwer Academic Publishers, 1998: 257-82.
13. Carney DN, Bunn PA, Gazdar AF, Pagan JA, Minna JD. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci U S A 1981; 78: 3185-9.
14. Cabrera T, Fernandez MA, Sierra A et al. High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 1996; 50: 127-34.
15. Garrido F, Cabrera T, Accolla RS et al. HLA and cancer. In: Charron D, ed. HLA, genetic diversity of HLA. Functional and medical implications. Vol I. Paris: EDK, 1997: 445-52.
16. Kocher T, Schultz-Tater E, Gudat F et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995; 55: 2236-9.
17. Gyapay G, Morissette J, Vignal A et al. The 1993-94 Genethon human genetic linkage map. Nat Genet 1994; 7: 246-339.
18. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991; 87: 284-92.
19. Cormier JN, Hijazi YM, Abati A et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75: 517-24.
20. Nistico P, Tecce R, Giacomini P et al. Effect of recombinant human leucocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res 1990; 50: 7422-9.
21. Smit N, Le Poole I, van den Wijngaard R, Tigges A, Westerhof W, Das P. Expression of different immunological markers by cultured human melanocytes. Arch Dermatol Res 1993; 285: 356-65.
22. Browning M, Petronzelli F, Bicknell D et al. Mechanisms of loss of HLA class I expression on colorectal tumor cells. Tissue Antigens 1996; 47: 364-371.
23. Maio M, Altomonte M, Tatake R, Zeff RA, Ferrone S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with β2m gene. J Clin Invest 1991; 88: 282-9.
24. Garrido F, Cabrera T, Lopez-Nevot MA, Ruiz-Cabello F. HLA class I antigens in human tumors. Adv Cancer Res 1995; 67: 155-95.